Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors (PEG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00834704
Recruitment Status : Completed
First Posted : February 3, 2009
Last Update Posted : March 26, 2013
Information provided by (Responsible Party):
Halozyme Therapeutics

Brief Summary:
Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: PEGPH20 Phase 1

Detailed Description:
This is a study of PEGPH20 in human subjects and is designed to evaluate the safety of PEGPH20 and to determine the maximum tolerated dose of PEGPH20. All patients will receive PEGPH20. Each group of patients will receive a higher dose than the previous group. This will continue until the group with the highest planned dose completes the study or until a group has major side effects from their assigned dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Study Start Date : February 2009
Actual Primary Completion Date : June 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Dose determination
Drug: PEGPH20
PEGylated recombinant human hyaluronidase

Primary Outcome Measures :
  1. To determine the recommended phase 2 dose (RP2D) of PEGPH20. To evaluate the safety and tolerability of PEGPH20 in advanced cancer patients over a range of doses. [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. To determine the pharmacokinetics (PK) of PEGPH20 [ Time Frame: 28 days ]
  2. To determine the dose-limiting toxicities (DLTs) of PEGPH20. [ Time Frame: 28 days ]
  3. To observe patients for any evidence of anti-tumor activity (efficacy). [ Time Frame: 28 days ]
  4. To explore pharmacodynamic endpoints that may guide the further development of PEGPH20. [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced solid tumor.
  • Patients who have experienced disease progression after receiving appropriate standard / approved chemotherapy and for whom no further standard or palliative treatment measures exist, or who have chosen to decline standard or palliative treatment.
  • One or more tumors measurable by RECIST criteria.
  • Karnofsky performance status ≥ 70%.
  • Recovery from any toxic or other effects of all previous therapy, including radiation, chemotherapy and surgery.
  • Negative serum or urine pregnancy test result in women of childbearing potential.
  • For men and women of child-producing potential, agreement to use effective contraception (hormonal or barrier birth control or abstinence) from the time of screening before study entry and throughout study participation.

Exclusion Criteria:

  • Brain metastasis.
  • New York Heart Association Class III or IV cardiac disease, myocardial infarction, or cardiac arrhythmia requiring medical therapy.
  • Known allergy to hyaluronidase.
  • Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions including psychiatric illness) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
  • Women currently breast feeding.
  • Concurrent participation in any other interventional therapeutic study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00834704

Layout table for location information
United States, Arizona
T Gen Clinical Research Services
Scottsdale, Arizona, United States, 85258
United States, California
Premiere Oncology
Santa Monica, California, United States, 90404
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Halozyme Therapeutics
Layout table for investigator information
Study Director: Joy Zhu, M.D. Halozyme Therapeutics
Layout table for additonal information
Responsible Party: Halozyme Therapeutics Identifier: NCT00834704    
Other Study ID Numbers: HALO-109-101
First Posted: February 3, 2009    Key Record Dates
Last Update Posted: March 26, 2013
Last Verified: September 2012
Keywords provided by Halozyme Therapeutics:
PEGylated recombinant human hyaluronidase
Metastatic or locally advanced solid tumor
Additional relevant MeSH terms:
Layout table for MeSH terms